SUN PHARMA

India’s largest drugmaker by revenue, reported a higher adjusted profit on Thursday, aided by strong domestic sales. The Mumbai-based firm’s consolidated profit before tax and exceptional items rose 16.6% to 39.91 billion rupees ($455.6 million) in the quarter ended June 30. The drugmaker reported a one-time charge of 8.18 billion rupees in the first quarter related to the impairment of certain assets and the settlement of a legal dispute. Accounting for the charge, profit fell nearly 20% on-year.